Last reviewed · How we verify
Different doses of Metoprolol.
Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload.
Metoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Angina pectoris, Acute myocardial infarction.
At a glance
| Generic name | Different doses of Metoprolol. |
|---|---|
| Sponsor | Xiangya Hospital of Central South University |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Metoprolol competitively blocks beta-1 adrenergic receptors on cardiac tissue, reducing the effects of catecholamines (epinephrine and norepinephrine). This leads to decreased heart rate, reduced contractility, and lower blood pressure. It is cardioselective at lower doses but can block beta-2 receptors at higher doses.
Approved indications
- Hypertension
- Angina pectoris
- Acute myocardial infarction
- Heart failure
- Arrhythmias
- Migraine prophylaxis
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Bronchospasm
- Sexual dysfunction
- Insomnia
Key clinical trials
- Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (PHASE2, PHASE3)
- Metoprolol in Patients With HFrEF and COPD (PHASE4)
- Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale (PHASE4)
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
- Different β -Blockers in STEMI and Primary PCI (NA)
- The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. (NA)
- Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: